blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2688585

EP2688585 - METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.07.2019
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  03.08.2018
FormerGrant of patent is intended
Status updated on  31.01.2018
FormerExamination is in progress
Status updated on  30.01.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
The Regents of the University of California
1111 Franklin Street, 12th Floor
Oakland, CA 94607 / US
[2018/36]
Former [2014/05]For all designated states
The Regents of the University of California
1111 Franklin Street 12th Floor
Oakland, CA 94607-5200 / US
Inventor(s)01 / CARBONELL, Warren, Shawn
OncoSynergy, Inc.
409 Illinois Street
San Francisco, CA 94158 / US
02 / AGHI, Manish, Kumar
University of California
505 Parnassus Avenue
Rm. M779
San Francisco, CA 94143 / US
 [2014/05]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2018/36]Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2014/05]Thom, Russell
Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL / GB
Application number, filing date12760157.322.03.2012
[2018/36]
WO2012US30204
Priority number, dateUS201161466791P23.03.2011         Original published format: US 201161466791 P
[2014/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012129448
Date:27.09.2012
Language:EN
[2012/39]
Type: A1 Application with search report 
No.:EP2688585
Date:29.01.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 27.09.2012 takes the place of the publication of the European patent application.
[2014/05]
Type: B1 Patent specification 
No.:EP2688585
Date:05.09.2018
Language:EN
[2018/36]
Search report(s)International search report - published on:US27.09.2012
(Supplementary) European search report - dispatched on:EP08.04.2015
ClassificationIPC:C07K16/22, C07K16/28, A61P35/00
[2018/07]
CPC:
A61P35/00 (EP); A61K39/395 (KR); A61K39/39558 (US);
A61K38/18 (KR); A61K48/00 (KR); A61K49/00 (US);
C07K16/22 (EP,US); C07K16/2842 (EP,US); A61K2039/505 (EP,US);
A61K2039/507 (EP,US); A61K2039/545 (EP,US); C07K2317/73 (EP,US);
C12N2740/15043 (EP,US) (-)
Former IPC [2014/05]A61K39/00, A61K39/395, A61K38/18, A61K48/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERBESSERUNG EINER ANTIANGIOGENTHERAPIE MIT ANTIINTEGRINEN[2014/05]
English:METHODS AND COMPOSITIONS FOR IMPROVING ANTIANGIOGENIC THERAPY WITH ANTI-INTEGRINS[2014/05]
French:PROCÉDÉS ET COMPOSITIONS POUR L'AMÉLIORATION D'UNE THÉRAPIE ANTI-ANGIOGÉNIQUE PAR DES ANTI-INTÉGRINES[2014/05]
Entry into regional phase01.10.2013National basic fee paid 
01.10.2013Search fee paid 
01.10.2013Designation fee(s) paid 
01.10.2013Examination fee paid 
Examination procedure01.10.2013Examination requested  [2014/05]
30.10.2015Amendment by applicant (claims and/or description)
23.06.2016Despatch of a communication from the examining division (Time limit: M06)
31.01.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
07.04.2017Reply to a communication from the examining division
09.01.2018Cancellation of oral proceeding that was planned for 15.01.2018
15.01.2018Date of oral proceedings (cancelled)
01.02.2018Communication of intention to grant the patent
30.05.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
30.05.2018Fee for grant paid
30.05.2018Fee for publishing/printing paid
14.06.2018Communication of intention to grant the patent
31.07.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  23.06.2016
Opposition(s)06.06.2019No opposition filed within time limit [2019/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
07.04.2017Request for further processing filed
07.04.2017Full payment received (date of receipt of payment)
Request granted
21.04.2017Decision despatched
Fees paidRenewal fee
27.03.2014Renewal fee patent year 03
27.03.2015Renewal fee patent year 04
31.03.2016Renewal fee patent year 05
27.03.2017Renewal fee patent year 06
27.03.2018Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.03.2012
AL05.09.2018
AT05.09.2018
CY05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
MK05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
TR05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
MT22.03.2019
[2022/31]
Former [2021/32]HU22.03.2012
AL05.09.2018
AT05.09.2018
CY05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
TR05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
MT22.03.2019
Former [2021/26]AL05.09.2018
AT05.09.2018
CY05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
TR05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
MT22.03.2019
Former [2020/29]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
TR05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
MT22.03.2019
Former [2020/17]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
TR05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
Former [2020/01]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
LU22.03.2019
Former [2019/46]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
MC05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
Former [2019/37]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SI05.09.2018
SK05.09.2018
SM05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
Former [2019/34]AL05.09.2018
AT05.09.2018
CZ05.09.2018
DK05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SK05.09.2018
SM05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
Former [2019/26]AL05.09.2018
AT05.09.2018
CZ05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SK05.09.2018
SM05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
PT05.01.2019
Former [2019/23]AL05.09.2018
AT05.09.2018
CZ05.09.2018
EE05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
SK05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
Former [2019/22]AL05.09.2018
CZ05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
PL05.09.2018
RO05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
Former [2019/21]AL05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
IS05.01.2019
Former [2019/20]AL05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
NL05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
Former [2019/12]AL05.09.2018
FI05.09.2018
HR05.09.2018
LT05.09.2018
LV05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
Former [2019/11]FI05.09.2018
HR05.09.2018
LT05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
Former [2019/10]FI05.09.2018
LT05.09.2018
RS05.09.2018
SE05.09.2018
BG05.12.2018
NO05.12.2018
GR06.12.2018
Former [2019/08]FI05.09.2018
LT05.09.2018
NO05.12.2018
Former [2019/07]LT05.09.2018
Documents cited:Search[I]WO2005117976  (UNIV CALIFORNIA [US], et al) [I] 1-12 * figure 6; example 5; claims 1-4 *;
 [X]WO2010111254  (GENENTECH INC [US], et al) [X] 1,2,4-7,10-12 * example 9 *;
 [XI]  - Carlos Mas-Moruno, "Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation", Anti-Cancer Agents in Medicinal Chemistry, (20101201), pages 753 - 768, URL: http://docstore.ingenta.com/cgi-bin/ds_deliver/1/u/d/ISIS/69969187.1/ben/acamc/2010/00000010/00000010/art00007/711E08525CEF25A8134434530600F42C4601B70289.pdf?link=http://www.ingentaconnect.com/error/delivery&format=pdf, (20120807), XP055034886 [X] 10 * page 761, column l, paragraph 2 - column r; table 4 * [I] 1-9,11,12

DOI:   http://dx.doi.org/10.2174/187152010794728639
 [I]  - KIM S ET AL, "Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin.", THE AMERICAN JOURNAL OF PATHOLOGY APR 2000, (200004), vol. 156, no. 4, ISSN 0002-9440, pages 1345 - 1362, XP002732579 [I] 1-12 * page 1352, column r, paragraph 2 - page 1354, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0002-9440(10)65005-5
 [I]  - SATHORNSUMETEE SITH ET AL, "Antiangiogenic therapy in malignant glioma: Promise and challenge", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, NL, (20070101), vol. 13, no. 35, ISSN 1381-6128, pages 3545 - 3558, XP002570212 [I] 1-12 * page 3545, column r, paragraph last; table 1 * * page 3553, column l, paragraph 2 - paragraph 3 *
 [I]  - MILETIC H ET AL, "Anti-VEGF therapies for malignant glioma: Treatment effects and escape mechanisms", EXPERT OPINION ON THERAPEUTIC TARGETS,, (20090401), vol. 13, no. 4, doi:10.1517/14728220902806444, ISSN 1472-8222, pages 455 - 468, XP009173289 [I] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1517/14728220902806444
 [I]  - SCOTT BRIAN J ET AL, "Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.", NEURO-ONCOLOGY JUN 2010, (201006), vol. 12, no. 6, ISSN 1523-5866, pages 603 - 607, XP002733159 [I] 1-12 * abstract *

DOI:   http://dx.doi.org/10.1093/NEUONC/NOP073
 [T]  - JAHANGIRI ARMAN ET AL, "[beta]1 integrin: Critical path to antiangiogenic therapy resistance and beyond.", CANCER RESEARCH 1 JAN 2014, (20140101), vol. 74, no. 1, ISSN 1538-7445, pages 3 - 7, XP002733162

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-13-1742
International search[A]US2003143191  (BELL ADAM [US], et al);
 [Y]WO2009009114  (ONCOMED PHARM INC [US], et al);
 [Y]US2009124976  (MITTERMEYER STEPHAN [DE]);
 [X]US2009220504  (CHUNTHARAPAI ANAN [US], et al);
 [Y]US2010048677  (MITCHELL W BEAU [US], et al)
by applicantUS4816567
 US5840300
 WO0042012
 WO0041698
 US6165467
 US2001003447
 US2001016659
 US2002013774
 US2002165394
 US2003125339
 US2003125359
 US6716410
 US2005038080
 US6878714
 US6949245
 US6995162
 US2006241115
 US2009304694
    - WERB, Z.; TREMBLE, P.; BERENSTEN, O.; CROWLEY, E.; DAMSKY, C. H., "Signal transduction through the fibronectin receptors induces collagenase expression", J. CELL BIOL., (1989), vol. 109, pages 877 - 890
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - HEMACHANDRA ET AL., "Human Monoclonal Antibodies against Pseudomonas aeruginosa Lipopolysaccharide Derived from Transgenic Mice Containing Megabase Human Immunoglobulin Loci Are Opsonic and Protective against Fatal Pseudomonas Sepsis", INFECTION AND IMMUNITY, (200104), vol. 69, no. 4, doi:doi:10.1128/IAI.69.4.2223-2229.2001, pages 2223 - 2229, XP002204809

DOI:   http://dx.doi.org/10.1128/IAI.69.4.2223-2229.2001
    - SCHIER ET AL., "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site", J MOL BIOL., (19961108), vol. 263, no. 4, doi:doi:10.1006/jmbi.1996.0598, pages 551 - 67, XP029808944

DOI:   http://dx.doi.org/10.1006/jmbi.1996.0598
    - TOMLINSON I.; HOLLIGER P., "Methods for generating multivalent and bispecific antibody fragments", METHODS ENZYMOL, (2000), vol. 326, doi:doi:10.1016/S0076-6879(00)26070-9, pages 461 - 479, XP001154118

DOI:   http://dx.doi.org/10.1016/S0076-6879(00)26070-9
    - FUJISAWA ET AL., "Catalytically inactive phospholipase A2 homologue binds to vascular endothelial growth factor receptor-2 via a C-terminal loop region", BIOCHEM. J., (2008), vol. 411, pages 515 - 522
    - J. CELL BIOL., (1987), vol. 105, no. 3, pages 1183 - 1190
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.